Lyme disease vaccination: are we ready to try again?

Lantos, Paul M.

doi:10.1016/s1473-3099(13)70085-9

Cited by 14 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A vaccine protecting against LB is currently unavailable in Europe, but a potential vaccine has recently been tested in a Phase I/II trial [ 208 , 209 ], and another LB vaccine is being developed for the European market as well [ 210 ]. Based on the experiences with a previous Lyme vaccine that was on the American market, with an effectivity between 62% and 85%, it remains to be seen whether a Lyme vaccine will be widely accepted and used, or only cost-effective for high risk groups [ 211 , 212 ]. Ideally, one would like to have a single vaccine for humans, protecting against multiple TBDs [ 213 ].…”

Section: Control Of Lb and Other I Ricinus -Bornementioning

confidence: 99%

Control of Lyme borreliosis and other Ixodes ricinus-borne diseases

et al. 2018

View full text Add to dashboard Cite

Lyme borreliosis (LB) and other Ixodes ricinus-borne diseases (TBDs) are diseases that emerge from interactions of humans and domestic animals with infected ticks in nature. Nature, environmental and health policies at (inter)national and local levels affect the risk, disease burden and costs of TBDs. Knowledge on ticks, their pathogens and the diseases they cause have been increasing, and resulted in the discovery of a diversity of control options, which often are not highly effective on their own. Control strategies involving concerted actions from human and animal health sectors as well as from nature managers have not been formulated, let alone implemented. Control of TBDs asks for a “health in all policies” approach, both at the (inter)national level, but also at local levels. For example, wildlife protection and creating urban green spaces are important for animal and human well-being, but may increase the risk of TBDs. In contrast, culling or fencing out deer decreases the risk for TBDs under specific conditions, but may have adverse effects on biodiversity or may be societally unacceptable. Therefore, in the end, nature and health workers together must carry out tailor-made control options for the control of TBDs for humans and animals, with minimal effects on the environment. In that regard, multidisciplinary approaches in environmental, but also medical settings are needed. To facilitate this, communication and collaboration between experts from different fields, which may include patient representatives, should be promoted.

show abstract

Section: Control Of Lb and Other I Ricinus -Bornementioning

confidence: 99%

Control of Lyme borreliosis and other Ixodes ricinus-borne diseases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…New vaccines in development could have greater commercial viability as they are designed to target multiple Borrelia or tick vectors, and thus work across larger geographic areas [19][20][21]. Nevertheless, they are still likely to face major barriers to widespread adoption [22]. Recommended precautionary behaviours designed to decrease the risk of being bitten by infected ticks include wearing light coloured clothes with long sleeves and trousers tucked into socks, the use of insecticide on skin and clothing, sticking to paths and avoiding walking through long grass [23,24].…”

Section: Introductionmentioning

confidence: 99%

Can interventions that aim to decrease Lyme disease hazard at non-domestic sites be effective without negatively affecting ecosystem health? A systematic review protocol

2016

View full text Add to dashboard Cite

Background: Lyme disease (LD) is the most commonly reported, broadly distributed vector-borne disease of the northern temperate zone. It is transmitted by ticks and, if untreated, can cause skin, cardiac, nervous system and musculoskeletal disease. The distribution and incidence of LD is increasing across much of North America and Western Europe. Interventions to decrease exposure to LD hazard by encouraging behavioural change have low acceptance in high risk groups, and a safe, effective human LD vaccine is not presently available. As a result, habitat level interventions to decrease LD hazard itself (i.e. levels of infected ticks) have been proposed. However, some interventions may potentially negatively affect ecosystem health, and consequentially be neither desirable, nor politically feasible. This systematic review will catalogue interventions that aim to reduce LD hazard at non-domestic sites, and examine the evidence supporting those which are unlikely to negatively affect ecosystem health. Methods:The review will be carried out in two steps. First, a screening and cataloguing stage will be conducted to identify and characterise interventions to decrease LD hazard at non-domestic sites. Secondly, the subset of interventions identified during cataloguing as unlikely to negatively affect ecosystem health will be investigated. In the screening and cataloguing step literature will be collected through database searching using pre-chosen search strings, hand-searching key journals and reviewing the websites of public health bodies. Further references will be identified by contacting stakeholders and researchers. Article screening and assessment of the likely effects of interventions on ecosystem health will be carried out independently by two reviewers. A third reviewer will be consulted if disagreements arise. The cataloguing step results will be presented in tables. Study quality will then be assessed independently by two reviewers, using adapted versions of established tools developed in healthcare research. These results will be presented in a narrative synthesis alongside tables. Though a full meta-analysis is not expected to be possible, if sub-groups of studies are sufficiently similar to compare, a partial meta-analysis will be carried out.

show abstract

“…A vaccine protecting against Lyme borreliosis is unavailable, but a refined vaccine has recently been tested in a Phase I/II trial [23]. Based on the experiences with the previous Lyme vaccine that was on the American market from 1998 to 2002, it remains to be seen whether a Lyme vaccine will be widely used [24]. There is no human vaccine to prevent babesiosis or any other of the other above-mentioned pathogens.…”

Section: Introductionmentioning

confidence: 99%

ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe

et al. 2014

View full text Add to dashboard Cite

Ixodes ricinus transmits bacterial, protozoal and viral pathogens, causing disease and forming an increasing health concern in Europe. ANTIDotE is an European Commission funded consortium of seven institutes, which aims to identify and characterize tick proteins involved in feeding and pathogen transmission. The knowledge gained will be used to develop and evaluate anti-tick vaccines that may prevent multiple human tick-borne diseases. Strategies encompassing anti-tick vaccines to prevent transmission of pathogens to humans, animals or wildlife will be developed with relevant stakeholders with the ultimate aim of reducing the incidence of tick-borne diseases in humans.

show abstract

Lyme disease vaccination: are we ready to try again?

Cited by 14 publications

References 15 publications

Control of Lyme borreliosis and other Ixodes ricinus-borne diseases

Control of Lyme borreliosis and other Ixodes ricinus-borne diseases

Can interventions that aim to decrease Lyme disease hazard at non-domestic sites be effective without negatively affecting ecosystem health? A systematic review protocol

ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe

Contact Info

Product

Resources

About